| Q38760623 | A catalogue of treatment and technologies for malignant pleural mesothelioma |
| Q37101238 | Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice |
| Q37070229 | Advances in the systemic therapy of malignant pleural mesothelioma |
| Q33738142 | Applications of high content screening in life science research |
| Q39351108 | Asbestos exposure induces alveolar epithelial cell plasticity through MAPK/Erk signaling |
| Q28393611 | Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways |
| Q35748646 | Autophagy Correlates with the Therapeutic Responsiveness of Malignant Pleural Mesothelioma in 3D Models |
| Q28533736 | BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma |
| Q27006075 | Boron chemicals in diagnosis and therapeutics |
| Q39725130 | Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells |
| Q52716160 | Bortezomib enhances radiosensitivity in oral cancer through inducing autophagy-mediated TRAF6 oncoprotein degradation. |
| Q39702665 | Characterization of bortezomib-adapted I-45 mesothelioma cells |
| Q35141369 | Chemotherapy and targeted therapies for unresectable malignant mesothelioma |
| Q48507691 | Combination therapy with proteasome inhibitors and TLR agonists enhances tumour cell death and IL-1β production. |
| Q38501336 | Dual blockade of PKA and NF-κB inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis |
| Q37549806 | FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis |
| Q37449036 | Future developments in the management of malignant pleural mesothelioma |
| Q45229028 | Gambogic acid is cytotoxic to cancer cells through inhibition of the ubiquitin-proteasome system |
| Q33890506 | In vitro experimental models of mesothelioma revisited |
| Q60395357 | Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma |
| Q34293068 | Investigational approaches for mesothelioma |
| Q28395597 | Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies |
| Q47098675 | Malignant mesothelioma: Canadian perspective and research directions |
| Q43195730 | Malignant pleural effusion: further translational research is crucial |
| Q38019747 | Malignant pleural mesothelioma: from the bench to the bedside. |
| Q36741548 | Mammalian target of rapamycin contributes to the acquired apoptotic resistance of human mesothelioma multicellular spheroids |
| Q37956213 | Metastases to the oral region from pleural mesothelioma: Clinicopathologic review. |
| Q38509951 | MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications |
| Q38012566 | Molecular pathogenesis of malignant mesothelioma |
| Q28397153 | Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma |
| Q52581757 | New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma. |
| Q36822739 | New applications of old metal-binding drugs in the treatment of human cancer |
| Q37360580 | New diagnostic and molecular characteristics of malignant mesothelioma |
| Q81274554 | New uses for old copper-binding drugs: converting the pro-angiogenic copper to a specific cancer cell death inducer |
| Q36159154 | Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma |
| Q47096168 | Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis |
| Q24612464 | Ranpirnase Interferes with NF-κB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth |
| Q37873380 | Review on clinical trials of targeted treatments in malignant mesothelioma |
| Q35621800 | Simian virus 40 transformation, malignant mesothelioma and brain tumors |
| Q34205125 | Synthetic lethal screen identifies NF-κB as a target for combination therapy with topotecan for patients with neuroblastoma |
| Q37260408 | Systemic treatments for mesothelioma: standard and novel |
| Q34614482 | Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines |
| Q38846141 | Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo |
| Q38347433 | The Bcl-2 repertoire of mesothelioma spheroids underlies acquired apoptotic multicellular resistance |
| Q35836872 | The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention |
| Q37806309 | Translational advances in pleural malignancies |
| Q35742519 | Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients. |
| Q28069036 | UBXD Proteins: A Family of Proteins with Diverse Functions in Cancer |
| Q33699231 | hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. |